+ Watch NVIV
on My Watchlist
will change treatment
trials are terricic,paraplegics are getting movement National news coming
Too much positive information has leaked from this companies clinical trials.
I might as well try and jump into this hyped-up run-up rather than trying to hold back the tsunami with my bare hands. As I've described in the past, InVivo has a very checkered history that I won't bother to rehash. After crashing from a hyped up run in 2013, the company divested itself of its controversial, promotional founder who then proceeded to start divesting himself of millions of company shares at a remarkable clip. All the insider selling and a lack of interest from the street brought the stock to a low of 0.5 in October. The stock has now resurged amidst a new round of promotional hype and some modestly good news from the FDA regarding the severity of enrollment restrictions in the ongoing clinical trial of biopolymer scaffolding for thoracic spinal injury. Apparently, the three month clinical assessment of the first recipient should be released this week, and stock touts are clamoring about media reports which claim dramatic improvement. We've seen this same tactic many times before with Stemcells, Neuralstem, Sarepta, and others, and it hasn't ever resulted in sustained appreciation in share price. Nevertheless, momentum seems to be on InVivo's side for now and I'll settle in for a CAPS-only ride in the biocrap amusement park.
The ratio of people to cake is too big.Milton
There’s lots of information out there on this stock already so I don’t feel it’s necessary for me to post a massive pitch. I encourage you to go read ZZLangerhans’ previous pitches and blogs about this stock as they do contain some key information that might be helpful. The stock has recently rebounded from its lows due to a recent press release: “InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.”It’s somewhat understandable that it bounced higher given the new CEO called it a “major milestone not only for the company, but also for the field of traumatic SCI.” That’s great and everything, but they are a very, very long ways off from having a viable, FDA-approved product. Shareholders have completely overreacted to what I believe is tepid news. Here's some key information I found: “InVivo Therapeutics Corporation (?InVivo?) was incorporated on November 28, 2005 under the laws of the State of Delaware. On October 26, 2010, InVivo completed a reverse merger transaction (the Merger?) with InVivo Therapeutics Holdings Corp. (formerly Design Source, Inc.) (?ITHC?), a publicly traded company incorporated under the laws of the State of Nevada. InVivo became a wholly owned subsidiary of ITHC, which continues to operate the business of InVivo. InVivo is a life sciences company focused on the development and commercialization of both novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions. The biopolymer devices are designed to protect and repair damaged tissue and to deliver drugs and other agents, including proteins. The post-merger combination of ITHC and InVivo is referred to throughout these notes to consolidated financial statements as the Company.”“In August 2013, Frank Reynolds, our former Chief Executive Officer and Chief Financial Officer, resigned from the Company, and Michael J. Astrue was appointed Interim Chief Executive Officer. Sean Moran, who was appointed Acting Chief Financial Officer following the resignation of Mr. Reynolds, subsequently resigned from the Company in September 2013. Shortly thereafter, Gregory D. Perry was appointed Interim Chief Financial Officer.”“Since its inception, InVivo has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. Accordingly, InVivo is considered to be in the development stage.”So you can easily see where this was reverse merged into existence. Anyone interested what the business plan was in 2005? Well, here you go (from a very early 2006 10-Q): “Part of our marketing program includes sourcing out and identifying interior designers and individual consumers who may become potential buyers of commercial upholstery, drapery, bedspread, panel, and wall-covering fabrics from our website. The process of sourcing out suppliers includes identifying manufacturers, large and small by research into existing databases via the internet and research in trade magazines and directories.” So in early 2006, the company was attempting to raise $50K in capital to sell drapes. And now they are attempting to sell spinal scaffold to patients of traumatic spinal injuries? That is one heck of a leap. Take a look at the second copy/paste from the 10-Q above; the CEO and CFO both resigned. Guess who owns a ton of shares and has been selling them on a pretty regular basis? I’ll give you three guesses and the first two don’t count. The third copy/paste above is enlightening for a number of reasons. Note the company has been around since 2005 and yet are still in the development stage? Does this raise a huge red flag for anyone else? I don’t see any revenue back through inception but I do see lots of reasons to avoid this stock like it’s contracted the black plague.
cured monkeys of spinal damage induced paralysis - next step, humansstock at an all time lowheavy accumulation indicates possible buyout target
The big IF is successfully navigating clinical human trials. If it does so then this has massive upside potential.
Next Top Dog and First Mover in medical device company.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions